CN109219610A - 拓扑异构酶毒物 - Google Patents

拓扑异构酶毒物 Download PDF

Info

Publication number
CN109219610A
CN109219610A CN201780034468.4A CN201780034468A CN109219610A CN 109219610 A CN109219610 A CN 109219610A CN 201780034468 A CN201780034468 A CN 201780034468A CN 109219610 A CN109219610 A CN 109219610A
Authority
CN
China
Prior art keywords
compound
alkyl
optionally
phenyl
unit monocycle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780034468.4A
Other languages
English (en)
Chinese (zh)
Inventor
E·J·拉沃伊
阿吉特·K·帕尔希
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rutgers, The State University of New Jersey
Original Assignee
Rutgers, The State University of New Jersey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rutgers, The State University of New Jersey filed Critical Rutgers, The State University of New Jersey
Publication of CN109219610A publication Critical patent/CN109219610A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
CN201780034468.4A 2016-04-04 2017-04-03 拓扑异构酶毒物 Pending CN109219610A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662318139P 2016-04-04 2016-04-04
US62/318,139 2016-04-04
PCT/US2017/025779 WO2017176648A1 (en) 2016-04-04 2017-04-03 Topoisomerase poisons

Publications (1)

Publication Number Publication Date
CN109219610A true CN109219610A (zh) 2019-01-15

Family

ID=60000629

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780034468.4A Pending CN109219610A (zh) 2016-04-04 2017-04-03 拓扑异构酶毒物

Country Status (6)

Country Link
US (1) US11091498B2 (cg-RX-API-DMAC7.html)
EP (1) EP3442979A4 (cg-RX-API-DMAC7.html)
JP (1) JP2019515025A (cg-RX-API-DMAC7.html)
CN (1) CN109219610A (cg-RX-API-DMAC7.html)
CA (1) CA3019945A1 (cg-RX-API-DMAC7.html)
WO (1) WO2017176648A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824771A (zh) * 2019-03-07 2019-05-31 中国药科大学 一种降糖肽及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022216696A1 (en) * 2021-02-05 2023-08-17 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Camptothecin compound, preparation method therefor, and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065448A2 (en) * 2004-11-18 2006-06-22 Threshold Pharmaceuticals, Inc. Topoisomerase inhibitors and prodrugs
CN101501054A (zh) * 2005-06-29 2009-08-05 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) 1961-04-25 Acridine derivatives
US2985661A (en) 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420045A (de) 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
US3267107A (en) 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (cg-RX-API-DMAC7.html) 1972-08-25 1974-04-22
US3912740A (en) 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US5153178A (en) 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4749708A (en) 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
US4980344A (en) 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
US4761417A (en) 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd 13−プロピルベルベリンの塩
FR2595356B1 (fr) 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
DE69430752T2 (de) 1993-09-28 2002-10-17 Kyowa Hakko Kogyo Co., Ltd. Tetracyclische verbindungen
US5807874A (en) 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
CA2221248A1 (en) 1995-05-17 1996-11-21 Leroy Fong Liu Tribenzimidazoles useful as topoisomerase i inhibitors
US5767142A (en) 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
PL328402A1 (en) 1996-02-12 1999-01-18 Rutgers Analoques of coralline as inhibitors of topoisomerase
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
BR9711296A (pt) 1996-09-23 1999-08-17 Univ Rutgers Composto processo terap-utico para inibir o crescimento de c-lulas de c ncer e composi-Æo farmac-utica
US6140328A (en) 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
WO2000021537A1 (en) 1998-10-14 2000-04-20 Purdue Research Foundation Novel indenoisoquinolines as antineoplastic agents
WO2001032631A2 (en) 1999-10-29 2001-05-10 Rutgers, The State University Of New Jerey Heterocyclic cytotoxic agents
US6740650B2 (en) 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
CA2467279A1 (en) 2001-11-14 2003-06-26 Edmond J. Lavoie Solubilized topoisomerase poison agents
DE60225943T2 (de) 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase-giftmittel
ATE405568T1 (de) 2001-11-14 2008-09-15 Univ Rutgers Cytotoxische mittel
AU2002363658B2 (en) 2001-11-14 2008-09-11 Rutgers, The State University Solubilized topoisomerase poisons
US6989387B2 (en) 2002-08-09 2006-01-24 Rutgers, The State University Of New Jersey Nitro and amino substituted topoisomerase agents
AU2003268075A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
US6992088B2 (en) 2002-08-09 2006-01-31 Rutgers, The State University Of New Jersey Nitro and amino substituted heterocycles as topoisomerase I targeting agents
AU2003290818A1 (en) 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
ES2605443T3 (es) 2003-11-06 2017-03-14 Seattle Genetics, Inc. Conjugados de auristatina con anticuerpos anti-HER2 o anti-CD22 y su uso en terapia
JP2010519310A (ja) * 2007-02-21 2010-06-03 メダレックス インコーポレイテッド 単一のアミノ酸を有する化学リンカーおよびその複合体
PE20090245A1 (es) * 2007-05-08 2009-03-17 Genentech Inc Anticuerpos anti-muc16 disenados con cisteina y conjugados de anticuerpos y farmacos
TW201038578A (en) 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
JP5773888B2 (ja) 2009-03-06 2015-09-02 ラットガーズ,ザ・ステート・ユニバーシティ・オブ・ニュージャージー 癌治療に用いられるメチレンジオキシベンゾ[i]フェナントリジン誘導体
WO2010127363A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
US20130280282A1 (en) * 2012-04-24 2013-10-24 Daiichi Sankyo Co., Ltd. Dr5 ligand drug conjugates
CN104822656B (zh) * 2012-05-15 2018-05-01 西雅图基因公司 自稳定接头偶联物
US9580511B2 (en) 2013-03-11 2017-02-28 Genzyme Corporation Site-specific antibody-drug conjugation through glycoengineering

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006065448A2 (en) * 2004-11-18 2006-06-22 Threshold Pharmaceuticals, Inc. Topoisomerase inhibitors and prodrugs
CN101501054A (zh) * 2005-06-29 2009-08-05 施瑞修德制药公司 氨基磷酸酯烷化剂前体药物

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANA L. SIMPLÍCIO等: "Prodrugs for Amines", 《MOLECULES》 *
SHEJIN ZHU等: "6-Substituted 6H-dibenzo[c,h][2,6]naphthyridin-5-ones: Reversed lactam analogues of ARC-111 with potent topoisomerase I-targeting activity and cytotoxicity", 《BIOORGANIC & MEDICINAL CHEMISTRY》 *
YANJUN YU等: "Comparative QSAR modeling of antitumor activity of ARC-111 analogues using stepwise MLR, PLS, and ANN techniques", 《MED CHEM RES》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109824771A (zh) * 2019-03-07 2019-05-31 中国药科大学 一种降糖肽及其应用
CN109824771B (zh) * 2019-03-07 2020-06-30 中国药科大学 一种降糖肽及其应用

Also Published As

Publication number Publication date
EP3442979A4 (en) 2019-12-18
WO2017176648A1 (en) 2017-10-12
EP3442979A1 (en) 2019-02-20
JP2019515025A (ja) 2019-06-06
US20200325149A1 (en) 2020-10-15
CA3019945A1 (en) 2017-10-12
US11091498B2 (en) 2021-08-17

Similar Documents

Publication Publication Date Title
Yao et al. Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: pharmaceutical strategy and clinical progress
JP6581630B2 (ja) 新規ベンゾジアゼピン誘導体
JP6784790B2 (ja) 標的化薬物結合体と使用するためのメチレンカルバメートリンカー
US10293053B2 (en) Silanol based therapeutic payloads
DK1651162T3 (en) IMPROVED CYTOTOXIC AGENTS WITH NEW MAYTANSINOIDS
CN109195631B (zh) 具有鹅膏毒肽的衍生物作为药物的抗体药物缀合物
JP2024038168A (ja) 生物活性分子コンジュゲート、その調製法及び使用
JP2024520283A (ja) 化学的カップリングリンカー及びその使用
CN107335061B (zh) 细胞毒性苯并二氮杂䓬衍生物
KR101413955B1 (ko) 아지리디닐-에포틸론 화합물
JP7239558B2 (ja) テトラマレイミドリンカー及びその使用
US20090036431A1 (en) Cytotoxic Agents Comprising New Tomaymycin Derivatives
WO2024175069A1 (zh) 喜树碱衍生物及其偶联物以及其制备方法和医药用途
JP2018507844A (ja) 抗体薬物コンジュゲート
EP4596550A1 (en) Compound usable in conjugation reaction and conjugate thereof
WO2023222019A9 (zh) 配体药物偶联物及其应用
US11091498B2 (en) Topoisomerase poisons
US9260478B2 (en) Potent and efficient cytotoxic peptides and antibody-drug conjugates thereof and their synthesis
KR102346268B1 (ko) 경구 항암 전구약물을 포함하는 복합체, 이의 제조방법 및 이의 용도
JP2026506849A (ja) 化学結合リンカー及びその用途
HK40104908A (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190115